Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for European expansion.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...

New Zealand said late on Thursday that it would make a commitment that by 2035 the country would have reduced emissions by 51 ...

WELLINGTON, New Zealand — A mountain in New Zealand considered an ancestor by Indigenous people was recognized as a legal person Thursday after a new law granted it all the rights and ...

New Nielsen data reveals NZ’s top automotive advertisers investing $124M, with Nissan surging and 22% of Kiwis planning new ...

Get Our Latest Stock Report on GSK GSK Stock Up 0.8 % GSK opened at $35.35 on Friday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The firm’s 50 day simple moving average is ...